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ABSTRACT:
An in vivo study in rats showed a cranberry juice product to inhibit
the intestinal first-pass metabolism of the CYP3A substrate nifed-
ipine. However, a clinical study involving the CYP3A probe sub-
strate midazolam and a different cranberry juice product showed
no interaction. Because the composition of bioactive components
in natural products can vary substantially, a systematic in vitro-in
vivo approach was taken to identify a cranberry juice capable of
inhibiting enteric CYP3A in humans. First, the effects of five cran-
berry juices, coded A through E, were evaluated on midazolam
1-hydroxylation activity in human intestinal microsomes. Juice E
was the most potent, ablating activity at 0.5% juice (v/v) relative to
control. Second, juice E was fractionated to generate hexane-,
chloroform-, butanol-, and aqueous-soluble fractions. The hexane-
and chloroform-soluble fractions at 50 g/ml were the most po-
tent, inhibiting by 77 and 63%, respectively, suggesting that the
CYP3A inhibitors reside largely in these more lipophilic fractions.
Finally, juice E was evaluated on the oral pharmacokinetics of
midazolam in 16 healthy volunteers. Relative to water, juice E
significantly increased the geometric mean area under the curve
(AUC)0- of midazolam by 30% (p  0.001), decreased the geo-
metric mean 1-hydroxymidazolam/midazolam AUC0- ratio by
40% (p < 0.001), and had no effect on geometric mean terminal
half-life, indicating inhibition of enteric, but not hepatic, CYP3A-
mediated first-pass metabolism of midazolam. This approach both
showed a potential drug interaction liability with cranberry juice
and substantiated that rigorous in vitro characterization of dietary
substances is required before initiation of clinical drug-diet inter-
action studies.
Cranberry juice has become popular as a natural alternative for the
prevention of urinary tract infections (UTIs), which have a high
incidence in women and elderly persons (Foxman, 2003; McMurdo et
al., 2005; Jepson and Craig, 2008). Moreover, cranberry juice has
shown efficacy in reducing UTIs in women with recurrent episodes
and in reducing bacteriuria in elderly persons (Avorn et al., 1994;
Stothers, 2002). Clinical benefits are associated with chronic use
(months) and with a regular frequency of consumption (daily) (Jepson
and Craig, 2008). Studies have shown that the prophylactic nature of
cranberry juice is a result of inhibition of the adhesion of bacterial
fimbriae to uroepithelial cells, rather than because of urinary acidifi-
cation (Liu et al., 2006; Gupta et al., 2007). Cranberry juice also has
shown a beneficial effect against drug-resistant bacteria (Howell and
Foxman, 2002), which could be important in institutional settings,
where nosocomial infections are frequent.
Despite these seemingly beneficial attributes, studies have suggested
that cranberry juice may be capable of eliciting clinically relevant inter-
actions with certain medications, albeit the literature is inconsistent. For
example, in rats, cranberry juice was as effective as grapefruit juice in
enhancing the systemic exposure of the calcium channel antagonist and
cytochrome P450 3A (CYP3A) substrate nifedipine (Uesawa and Mohri,
2006). Compared with saline, both grapefruit juice and cranberry juice
significantly increased the area under the curve (AUC) of nifedipine
by 60%. Moreover, similar to grapefruit juice, cranberry juice seemed
to inhibit enteric, but not hepatic, CYP3A-mediated first-pass metab-
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olism, as exemplified by the lack of effect on drug systemic half-life.
In contrast, a human study involving the CYP3A substrate cyclospor-
ine and cranberry juice indicated no interaction (Grenier et al., 2006).
However, cyclosporine is also a substrate for the enteric efflux trans-
porter P-glycoprotein (P-gp), which complicates the interpretation of
whether cranberry juice inhibits enteric CYP3A. In addition, only a
single glass (240 ml) of juice was given, which conflicts with the
general recommendation of consuming several glasses daily for the
prevention of UTIs (Lynch, 2004). Most recently, Lilja et al. (2007)
reported that cranberry juice, taken thrice daily for 10 days, had no
effect on the pharmacokinetics of the CYP3A probe substrate mida-
zolam, which was administered as a single oral dose on day 5.
Although a more appropriate probe substrate and real-life scenario of
long-term exposure was examined, some comments warrant mention.
In particular, no rationale was provided as to why cranberry juice was
taken for 10 days, why midazolam was given on day 5, or why a
sample size of 10 was chosen. Nevertheless, the current literature
suggests that cranberry juice has a drug interaction liability for rats,
but not humans, and thus has no clinical concerns.
An oversight to the aforementioned conclusion is that each study
examined a single brand of juice, which, like all products derived
from natural substances, vary considerably in the composition of
bioactive ingredients (Paine and Oberlies, 2007). Accordingly, an
alternate conclusion is that the product tested in the rat study con-
tained a suite of CYP3A inhibitory compounds at an aggregate con-
centration sufficient to elicit an inhibitory effect in vivo, whereas the
products used in the clinical studies did not. However, this supposition
is not easily assessable because none of the authors reported an in
vitro characterization of the test juice with respect to enteric CYP3A
inhibitory activity before initiation of the in vivo study. Because such
a priori testing is required for evaluation of the metabolic consequence
of new chemical entities, it follows that similar procedures should be
implemented for evaluation of the effects of dietary substances on
drug disposition (Paine and Oberlies, 2007).
Based on the inconsistencies in the literature regarding a potential
cranberry juice effect, along with the challenges that present when
evaluating the drug interaction liability of a dietary substance, cran-
berry juice was selected as a model substance to test the hypothesis
that a systematic approach should be used to identify clinically rele-
vant drug-diet interactions prospectively. First, multiple cranberry
juice products were tested as inhibitors of enteric CYP3A activity
using midazolam and human intestinal microsomes. Second, the most
potent juice was fractionated using established natural products chem-
istry techniques, and the resultant fractions were tested as inhibitors of
enteric CYP3A activity. Third, the physicochemical effects of the
selected test juice on the absorption of midazolam were evaluated
using the human intestinal cell line Caco-2. Finally, the test juice was
evaluated on the oral pharmacokinetics of midazolam in healthy
volunteers. This approach identified a cranberry juice that elicited a
pharmacokinetic interaction with an established CYP3A probe sub-
strate, substantiating that a rigorous in vitro characterization of a
dietary substance should be undertaken before initiation of a clinical
drug-diet interaction study. These observations also raise concerns for
individuals taking certain medications concomitantly with certain
brands of cranberry juice.
Materials and Methods
Materials and Chemicals. Human intestinal microsomes (HIMs) were
prepared previously from mucosal scrapings obtained from the jejunal portion
of a donor small intestine that was shown to be devoid of readily detectable
CYP3A5 immunoreactive protein using a selective anti-CYP3A5 antibody
(Paine et al., 2006). Baculovirus-insect cell-expressed CYP3A4 and CYP3A5
(coexpressed with cytochrome P450 reductase but not supplemented with
cytochrome b5) and 1-hydroxymidazolam (used for analysis of the in vitro
samples) were purchased from BD Gentest (Woburn, MA). Midazolam mal-
eate, alprazolam, ketoconazole, NADPH, ammonium hydroxide (28% in wa-
ter), and formic acid were purchased from Sigma-Aldrich (St. Louis, MO).
BioCoat culture inserts (4.2 cm2; BD Biosciences, San Jose, CA), murine
laminin, Dulbecco’s modified Eagle’s medium, nonessential amino acids,
vitamin E, gentamicin, sodium selenite, and zinc sulfate were purchased from
sources as described previously (Mouly et al., 2004). Fetal bovine serum was
purchased from Lonza Walkersville Inc. (Walkersville, MD). Disposable sy-
ringe filters (Uniflo25, pore size 0.2 m) were purchased from Whatman
Schleicher and Schuell (Keene, NH). 1-Hydroxymidazolam and d4-1-hy-
droxymidazolam (used for the analysis of human plasma) were purchased from
Cerilliant (Round Rock, TX). Methanol, hexane, chloroform, and acetonitrile
were high-performance liquid chromatography (HPLC) grade (Thermo Fisher
Scientific, Waltham, MA); 1-butanol was aqueous counting scintillant reagent
grade (Mallinckrodt Baker, Inc., Phillipsburg, NJ).
Natural Study Materials and Extraction/Fractionation of Cranberry
Juice from Vendor E. The following bottled, nonfrozen juices, which con-
tained cranberry juice in some form, were purchased from a local grocery
store: Lakewood Organic Fresh Pressed Blend Cranberry (Lakewood, Miami,
FL; Lot 147H), Ocean Spray Cranberry Juice Cocktail (Ocean Spray Cranber-
ries, Inc., Lakeville-Middleboro, MA; Lot B0513060220), Market Pantry Juice
Cocktail Cranberry (Target Corp., Minneapolis, MN: Lot 11F 13:11), 365
Brand 100% Cranberry Juice (Whole Foods Market, Austin, TX; Lot 02/17/
08), and R.W. Knudsen Family Cranberry Juice Concentrate (Knudsen and
Sons, Inc., Orville, OH). As described in the labeling, the Lakewood brand
contained fresh pressed juice and puree from whole ripe certified organic
apples, organic cranberries, and organic grapes; the Ocean Spray brand con-
tained filtered water, 27% cranberry juice (from concentrate and cranberry
juice), high fructose corn syrup, and ascorbic acid; the Market Pantry brand
contained filtered water, high fructose corn syrup, 27% cranberry juice (from
concentrate), and ascorbic acid; the 365 brand contained filtered water, cran-
berry juice, and cranberry juice concentrate; and the Knudsen brand was a
cranberry juice concentrate that contained no added sugars or other fruit juices.
To avoid any perceived conflicts of interest, the identities of the juices were
coded as vendors A, B, C, D, and E.
The juice from vendor E was extracted and fractionated using natural
products chemistry techniques, combining methods that were developed for
processing liter-scale bacterial cultures (Cain et al., 2003) with those that were
optimized for dried plant materials (Kinghorn et al., 2003; Phifer et al., 2007)
(Fig. 1). In brief, 1.6 liters of juice were freeze-dried; the resultant powder was
sonicated in methanol; and the entire suspension was stirred overnight. Solids
were removed via filtration, and the eluent was reduced in vacuo to yield a
methanol extract. This extract was partitioned between 9:1:10 methanol/water/
hexane, yielding a hexane fraction and an aqueous methanol fraction. The
latter was partitioned subsequently between 4:1:5 chloroform/methanol/water.
The lower organic layer was removed and dried in vacuo to yield the chloro-
form-soluble fraction. The upper aqueous layer was shaken with 1-butanol to
yield a 1-butanol fraction and an aqueous fraction. Each of the four resultant
fractions (hexane-, chloroform-, butanol-, and aqueous-soluble) was dried in
vacuo and stored at 80°C before in vitro testing.
In Vitro Characterization of Commercially Available Cranberry
Juices. Testing of whole cranberry juices as inhibitors of enteric CYP3A4
activity. The inhibitory effects of the five cranberry juice products on mida-
zolam 1-hydroxylation were evaluated using CYP3A5-negative HIMs. Mida-
zolam and ketoconazole were dissolved in methanol to yield stock solutions of
3 and 2 mM, respectively. These stock solutions were further diluted in water
and methanol, respectively, to yield working concentrations of 0.3 and 0.2
mM. Each cranberry juice was diluted in water to yield working concentrations
of 1 and 10% (v/v). NADPH was prepared fresh in potassium phosphate buffer
(0.1 M, pH 7.4) to yield a working concentration of 10 mM. Incubation
mixtures consisted of HIMs (0.05 mg/ml microsomal protein), midazolam (3
M), cranberry juice (0.05 or 0.5%), and potassium phosphate buffer (0.1 M,
pH 7.4); control incubation mixtures contained water in place of cranberry
juice. As a positive control for CYP3A inhibition, incubation mixtures were
prepared that contained ketoconazole (2 M) in place of cranberry juice;
control incubation mixtures contained 1% methanol in place of ketoconazole.
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All the incubation mixtures were equilibrated in a shaking water bath at 37°C
for 5 min before initiating the reactions with NADPH (1 mM final concentra-
tion) to yield a final volume of 200 l. After 4 min, 100-l aliquots were
removed and mixed with 200 l of acetonitrile containing 0.02 g/ml internal
standard (alprazolam). After centrifugation (1450g for 10 min at 4°C), the
supernatants were analyzed for 1-hydroxymidazolam by HPLC/tandem mass
spectrometry (MS/MS) as described previously (Wang et al., 2007). The
amount of 1-hydroxymidazolam formed was linear with respect to incubation
time and mass of microsomal protein.
Testing of fractions prepared from cranberry juice E on CYP3A activity.
Each of the four fractions prepared from cranberry juice E was dissolved in
methanol to yield working concentrations of 1 and 5 mg/ml. Incubation
mixtures were prepared in a similar manner as described in the preceding
section, only the whole juice was replaced with juice fraction (10 or 50 g/ml),
and control incubation mixtures contained 1% methanol in place of juice
fraction. The inhibitory effects of cranberry juice E and corresponding frac-
tions were also tested with recombinant CYP3A4 and CYP3A5 (rCYP3A4 and
rCYP3A5, respectively). Incubation mixtures were prepared in a similar man-
ner, only the HIMs were replaced with rCYP3A (10 pmol/ml). The reaction
mixtures were further processed and analyzed for 1-hydroxymidazolam as
described in the preceding section. The amount of 1-hydroxymidazolam
formed was linear with respect to incubation time and amount of rCYP3A
enzyme.
Evaluation of potential physicochemical effects of cranberry juice E on
midazolam absorptive permeability in Caco-2 cell monolayers. The Caco-2
cell clone P27.7 (Schmiedlin-Ren et al., 1997), passage 24, was seeded onto
laminin-coated BioCoat culture inserts (4.2 cm2/insert; BD Biosciences) at a
density of 4  105 cells/cm2 as described previously (Mouly et al., 2004).
Cell cultures were maintained in complete growth medium (Mouly et al., 2004)
until reaching confluence, when transepithelial electrical resistance (TEER)
was 250 -cm2. On reaching confluence (5 days postseeding), the cells
were maintained in differentiation medium (Mouly et al., 2004) for 3 weeks.
Throughout the experimental period, cell cultures were maintained in a hu-
midified incubator at 37°C and 5% carbon dioxide air atmosphere.
Plain incubation medium (differentiation medium devoid of fetal bovine
serum) served as the control solution. The high sugar content solution was
prepared by dissolving common table sugar (the same as that used in the
clinical study) in incubation medium at a concentration of 50 g/l. The low pH
solution was prepared by adjusting the incubation medium pH (7.4) to 5.5 with
5 N hydrochloric acid. Both the high sugar and low pH solutions were
sterile-filtered using 0.2-m disposable syringe filters. The cranberry juice
solution was prepared on the day of the experiment by diluting juice E with
incubation medium to yield a 25% juice (1 part concentrate/12 parts water,
according to the manufacturer’s labeling) and adjusting the pH from 2.5 to 7.4
with 1 N sodium hydroxide. Because the molecular mass(es) of the potential
CYP3A inhibitor(s) in the selected juice was not known, the 25% juice was not
sterile-filtered so as to retain all the active and inactive ingredients.
The control and three treatment solutions were spiked with midazolam to
yield a final concentration of 3 M (0.1% v/v methanol). Control or treatment
solution (1.5 ml) was added to the apical side, and plain incubation medium
(1.5 ml) was added to the basolateral side of triplicate culture inserts. After 0,
0.25, 0.5, 1, 2, 3, and 4 h at 37°C, a 20-l aliquot was collected from the apical
and basolateral compartment of each insert and transferred to the wells of a
96-well plate, each of which contained 80 l of water, followed by 200 l of
acetonitrile. TEER was measured at each time point to assess monolayer
integrity. After the 4-h collection, the remaining apical and basolateral media
were aspirated, and the remaining cells were collected by scraping into 400
l of cold incubation medium, followed by 1.2 ml of acetonitrile. All the
apical, basolateral, and cell collections were stored at 80°C pending
analysis for midazolam by HPLC/MS/MS (Wang et al., 2007) using the
characteristic single reaction monitoring transition, m/z 326.3 3 291.1.
Calibration standards were prepared in Dulbecco’s modified Eagle’s me-
dium and ranged from 15 to 5000 nM.
The apparent permeability coefficient (Papp) of midazolam in the apical
to basolateral direction was calculated according to the following equation:
Papp  (dQ/dt)  (1/AC0), where dQ/dt denotes the rate of midazolam
translocation from the apical to the basolateral compartment under sink con-
ditions (i.e., before 10% of the initial dose translocated to the basolateral
compartment), A denotes the surface area of the culture insert (4.2 cm2), and
C0 denotes the concentration of midazolam in the apical compartment at time 0.
Human Volunteer Study. Clinical protocol and study subjects. Both the
University of North Carolina Office of Human Research Ethics/Biomedical
Institutional Review Board and Clinical Research Advisory Committee re-
viewed and approved the study protocol. Written informed consent and Health
Insurance Portability and Accountability Act authorization were obtained from
each volunteer before participation. Healthy men and nonpregnant women
(eight each) were enrolled, excluding one man and one woman who withdrew
during the first phase because of a scheduling conflict and discomfort from
venipuncture, respectively. The men ranged in age from 20 to 58 years and the
women from 24 to 52 years. The participants were self-identified as white (four
men, six women), African American (three men, one woman), Hispanic (one
man), or Asian (one woman). Before enrollment, each participant underwent a
medical history, physical exam, liver function tests, and complete blood count.
Each woman also underwent a serum pregnancy test. None of the participants
were taking known modulators of CYP3A activity, except for two women (one
white, one African American) who were taking oral contraceptives for at least
5 to 7 years and assumed to be at steady state. Other concomitant medications
included levothyroxine (one white woman), hydrochlorothiazide (one white
woman), and multivitamin (one white woman and one African American
woman).
Preparation of double-strength cranberry juice. The selected cranberry
juice (E) was reconstituted with half the recommended volume of water to
yield a 200% concentrated juice. To minimize the variation in ingredients,
multiple bottles of juice from the same lot were combined to yield a single
stock concentrate. Common table sugar (Dixie Crystals, Port Wentworth, GA)
was added (5 g/oz, or 166 g/l) to improve palatability.
Study design. A prospective randomized, crossover, open-label study was
conducted at the University of North Carolina General Clinical Research
Center. The participants were asked to abstain from all fruit juices 1 week
before and during the study and from alcohol and caffeinated beverages the
evening before each study day. Participants were admitted to the General
Clinical Research Center the evening before each of two study phases, which
were separated by at least a 2-week interval. All the women underwent a repeat
serum pregnancy test on admission for each phase. Vital signs (blood pressure,
temperature, pulse, respirations) and oxygen saturation were obtained on
admission and monitored periodically throughout each phase. After an over-
night fast, each participant was given three 240-ml glasses of water or double-
strength cranberry juice, each separated by a 15-min interval. The participant
was given 5 mg of midazolam syrup (Roxane Laboratories, Inc., Columbus,
FIG. 1. Extraction and fractionation scheme used for the processing of cranberry
juice from vendor E. a The weights for the butanol- and aqueous-soluble fractions
are approximate. Because of the large size, it is difficult to remove all the residual
solvent, which could raise the measured weights slightly.
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OH) with the third glass. Blood (5 ml) was collected by venous puncture from
an indwelling catheter before dosing and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and
12 h postdose. Blood was centrifuged within 1 h of collection; plasma was
saved and stored at 20°C pending analysis for midazolam and 1-hydroxymi-
dazolam. Stability studies have shown that both analytes are stable in human
plasma at 20°C for 6 months, varying at most by 15% of nominal (A.D.M.
Kashuba, unpublished observations). Accordingly, all the plasma samples were
analyzed within 6 months of collection.
Analysis of Human Plasma for Midazolam and 1-Hydroxymidazolam.
Midazolam. Concentrations of midazolam were determined using a modified,
validated reverse-phase HPLC method with mass spectrometric detection
(Kanazawa et al., 2004). In brief, 300 l of plasma was added to 100 l of
methanol containing 10 ng/ml alprazolam (internal standard). The diluted
plasma was extracted with 1.5 ml of t-butyl ether, evaporated to dryness using
a TurboVap LV Evaporator (Caliper Life Sciences, Hopkinton, MA) at 30°C
for 10 min, and reconstituted with 100 l of an acetonitrile/water/acetic acid
mixture before injection onto an Agilent Technologies (Santa Clara, CA) 1100
LC-MSD system. Analytes were separated using a Luna C8 column (3.0 m,
2  100 mm; Phenomenex, Torrance, CA) and a gradient elution with a flow
rate of 200 l/min. Calibration curves ranged from 0.1 to 500 ng/ml. Interday
and intraday coefficients of variation across the range of concentrations were
less than 8%.
1-Hydroxymidazolam. Plasma (0.5 ml) was transferred to 1.5-ml amber
tubes and diluted with 0.5 ml of Dulbecco’s phosphate-buffered saline, after
which 8.5 l of the internal standard, d4-1-hydroxymidazolam (1.0 g/ml),
was added. Solid-phase extraction (SPE) was carried out using Strata-X
reverse-phase polymeric cartridges (33 m, 60 mg, 3 ml; Phenomenex). SPE
cartridges were conditioned with 2 ml of methanol, equilibrated with 3 ml of
water, and loaded with 1 ml of the diluted plasma. The SPE cartridges were
washed, successively, with 2 ml of water, 2 ml of water/0.1% ammonium
hydroxide, and twice with 2 ml of 95:5:0.1 water/acetonitrile/ammonium
hydroxide. The washed columns were dried under suction for 1 min and eluted
into amber tubes with 1.2 ml of acetonitrile/0.1% ammonium hydroxide. All
the tubes were dried partially under a nitrogen atmosphere overnight (to 400
l) and then dried to completion in a Speedvac (SVC-200H; Thermo Fisher
Scientific). All the SPE purification steps were performed under low light
conditions. Residues were resuspended in 400 l of 90:10:0.1 water/acetoni-
trile/ammonium hydroxide for analysis by HPLC/MS/MS. Calibration stan-
dards and quality controls were prepared in blank human plasma (SeraCare
Life Sciences, Inc., Milford, MA) and purified by SPE following the same
procedures. Calibration curves ranged from 0.05 to 120 ng/ml. Quality controls
were 0.35 and 17 ng/ml.
HPLC/MS/MS analysis was performed using a PE-Sciex API-365 triple
quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) coupled
with a PerkinElmer Life and Analytical Sciences (Waltham, MA) 200 series
micro-HPLC system. Liquid chromatography was carried out via 100-l
injections with a Luna C18(2) column (3 m, 50  2.0 mm; Phenomenex)
maintained at 30°C. The mobile phase, at a flow rate of 300 l/min, consisted
of water (solvent A) and acetonitrile (solvent B), both modified with 0.1%
ammonium hydroxide (v/v). A linear gradient was used that changed the A/B
solvent ratio from 95:5 to 5:95 over 4 min, before re-equilibration to the initial
conditions for 6 min. A diverter valve redirected the column effluent to waste
during the initial and later part of the gradient, during times when the com-
pounds of interest did not elute. General MS conditions were as follows:
source, Turbo Ionspray (electrospray ionization); ion polarity, positive; spray
voltage, 5000 V; source gas, nitrogen; nebulizer gas flow and curtain gas flow,
12 arbitrary units each; Turbo Ionspray gas flow, 6 l/min; source temperature,
375°C; scan type, multiple reaction monitoring; collision gas, nitrogen; colli-
sion gas pressure, 6 arbitrary units. Multiple reaction monitoring conditions for
the [MH] ions of both 1-hydroxymidazolam (m/z 342 3 203) and d4-1-
hydroxymidazolam (3463 203) were as follows: dwell time, 100 ms; declus-
tering potential, 36 V; focusing potential, 170 V; collision energy, 38 eV. The
following parameters were additionally used: entrance potential, 10 V; Q1
and Q3 resolution, both unit. Quantification of 1-hydroxymidazolam was
carried out using Analyst (version 1.1; Applied Biosystems). Interday vari-
ability in the assay averaged less than 7%.
Pharmacokinetic Analysis. The pharmacokinetics of midazolam and 1-
hydroxymidazolam were evaluated by noncompartmental methods using Win-
Nonlin (version 4.1; Pharsight, Mountain View, CA). The terminal elimination
rate constant (z) was estimated by linear regression of the terminal portion of
the log-transformed concentration versus time curve using at least the last three
data points in the terminal elimination phase. The terminal half-life (t1/2) was
calculated as ln(2)/z. The maximum observed concentration (Cmax) and time
to reach Cmax (Tmax) were obtained directly from the concentration-time
profile. The AUC from time 0 to the last measured concentration (Clast),
AUClast, was determined using the trapezoidal rule with linear up/log down
interpolation. The AUC from zero to infinite time (AUC0-	) was calculated as
the sum of AUClast and the ratio of Clast to z. The apparent oral clearance of
midazolam (Cl/F) was calculated as the ratio of dose to AUC0-	. The metab-
olite/parent AUC ratios (AUCm/AUCp) were calculated as the ratio of the AUC
for 1-hydroxymidazolam to the AUC for midazolam.
Statistical Analysis. All the statistical analyses were performed using
SigmaStat (version 3.5; Systat Software, Inc., San Jose, CA). The in vitro data
are presented as mean 
 S.D. of triplicate determinations. Comparisons
between the different brands and concentrations of cranberry juice involving
HIMs, between the four cranberry juice E-generated fractions and concentra-
tions involving HIMs, between rCYP3A4 and rCYPA5 with respect to the two
concentrations of juice E, and between the juice E-generated fractions and
concentrations involving rCYP3A4 and rCYP3A5 were made using a two-way
analysis of variance (ANOVA). For the Caco-2 cell experiment, comparisons
between Papp values were made using a one-way ANOVA. Comparisons
between treatment groups at each time point were made using a two-way
repeated-measures ANOVA. All the post hoc comparisons were made using
Tukey’s test when an overall difference resulted (p  0.05).
The sample size for the clinical study (n  16) was calculated based on an
80% power to detect a 25% difference in midazolam AUC0-	 between cran-
berry juice and water. Medians and ranges are reported for Tmax. The Wilcoxon
signed-rank test was used to detect a difference in Tmax. Geometric means and
coefficients of variation (100  S.D. of the natural log-transformed values) are
presented for Cmax, AUClast, AUC0-	, Cl/F, terminal t1/2, and metabolite/parent
AUC ratios. Geometric means and 90% confidence intervals are presented for
the ratio of cranberry juice to water with respect to Cmax, AUClast, AUC0-	,
Cl/F, and terminal t1/2. Paired two-tailed Student’s t-tests based on log-
transformed data were used to detect differences between cranberry juice and
water treatments. A p value 0.05 was considered statistically significant.
Results
Inhibitory Effects of Multiple Brands of Cranberry Juice on
Enteric CYP3A Activity in Vitro. Whole cranberry juice from five
different vendors (A, B, C, D, E) was tested as an inhibitor of
midazolam 1-hydroxylation activity in HIMs. Preliminary experi-
ments had shown that the two concentrations of juice tested (0.05 and
0.5%) were high enough to discern a differential response between
brands, but not so high as to ablate activity. Juices from vendors B, C,
D, and E inhibited activity in a concentration-dependent manner (Fig.
2A). Moreover, the extent of inhibition varied with vendor. At the
lower concentration of juice tested, relative to control, the extent of
inhibition ranged from 34% (juice A) to 66% (juice E). Only juice E
differed significantly from the other juices. At the higher concentra-
tion of juice tested, the extent of inhibition ranged from 43% (juice A)
to 100% (juices D and E). Juices C, D, and E differed significantly
from juices A and B, and juice B differed significantly from juice A.
The CYP3A inhibitor ketoconazole (2 M) abolished activity relative
to control in this and all the subsequent experiments (data not shown).
Because the cranberry juice from vendor E showed the greatest
extent of inhibition in HIM (Fig. 2A), juice E was selected for further
characterization. Using natural products chemistry techniques, this
juice was extracted/fractionated to generate a hexane-, chloroform-,
butanol-, and aqueous-soluble fraction (Fig. 1). To characterize the
fraction(s) most concentrated in the CYP3A inhibitory components,
each fraction was tested in HIMs. Relative to control, all the fractions
inhibited midazolam 1-hydroxylation in a concentration-dependent
manner (Fig. 2B). At the lower concentration tested (10 g/ml), the
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extent of inhibition was at most 35% (hexane-soluble fraction). The
hexane-soluble fraction differed significantly from the butanol-
soluble fraction. At the higher concentration tested (50 g/ml), the
hexane- and chloroform-soluble fractions were the most potent, in-
hibiting by 77 and 63%, respectively. Both of these fractions differed
significantly from the butanol- and aqueous-soluble fractions, and the
hexane-soluble fraction differed significantly from the chloroform-
soluble fraction.
The polymorphic CYP3A5 has been reported to be less sensitive
than CYP3A4 to inhibition by some therapeutic agents, which could
influence the extent of total CYP3A metabolism in some individuals
(Isoherranen et al., 2008). As such, the inhibitory effects of juice E
and its four derived fractions on midazolam 1-hydroxylation activity
were compared between rCYP3A4 and rCYP3A5. As observed with
HIMs, the whole juice inhibited activity in both rCYP3A enzymes in
a concentration-dependent manner (Fig. 3). At the lower concentra-
tion of juice tested (0.05%), rCYP3A5 was inhibited to a lesser extent
than rCYP3A4, whereas at a 10-fold higher concentration, activity
was abolished in both enzymes. All the fractions generated from juice
E inhibited both rCYP3A enzymes in a concentration-dependent
manner (Fig. 4). At a concentration of 10 g/ml, the extent of
inhibition toward rCYP3A4 varied from 10% (butanol-soluble) to
50% (hexane-soluble) (Fig. 4A); the extent of inhibition toward
rCYP3A5 varied from 0% (chloroform-soluble) to 23% (hexane-
soluble) (Fig. 4B). For both rCYP3A enzymes, the hexane-soluble
fraction differed significantly from all the other fractions. At a con-
centration of 50 g/ml, the hexane- and chloroform-soluble fractions
were the most potent toward rCYP3A4, inhibiting activity by at least
75% (Fig. 4A). Both of these fractions differed significantly from the
butanol- and aqueous-soluble fractions, and the hexane-soluble frac-
tion differed significantly from the chloroform-soluble fraction. Only
the hexane-soluble fraction showed significant inhibition toward
rCYP3A5 (62%) (Fig. 4B). Only the chloroform-soluble fraction
showed an appreciable difference between rCYP3A4 and rCYP3A5,
with rCYP3A4 being more sensitive to inhibition than rCYP3A5 (75
versus 18%).
Effects of Cranberry Juice E on Midazolam Absorption in
Caco-2 Cells. The combined physicochemical properties of the clin-
ical test cranberry juice (juice E) and midazolam prompted an eval-
uation of selected conditions on the absorption of midazolam. First,
cranberry juice per se is highly acidic and is sweetened routinely with
sugar to improve palatability (Raz et al., 2004); as measured in our
laboratory, the pH of juice E was 2.5. Second, at an environmental pH
below 4, the diazepam ring of midazolam opens, forming a more polar
primary amine derivative (Smith et al., 1981). Third, a high glucose
concentration has been shown to disrupt the membrane integrity of
Caco-2 cell monolayers (D’Souza et al., 2003). Taken together, these
observations raised the possibility that sweetened cranberry juice E
could alter the absorption of midazolam in vivo. Accordingly, the
potential physicochemical effects of cranberry juice E on the absorp-
tive permeability of midazolam were evaluated using Caco-2 cell
monolayers. The following conditions were tested: acidic pH (5.5),
high glucose concentration (50 g/l, pH 7.4), and diluted/neutralized
cranberry juice (25% juice, pH 7.4).
Under all the conditions, the TEER measurements exceeded 500
-cm2 and varied 20% over the 4-h experiment, indicating that
membrane integrity remained intact with both treatment and time.
Under all the treatment conditions, the rate of midazolam appearance
in the basolateral compartment was approximately linear up to 1 h
(Fig. 5). The Papp value under control, acidic, high glucose, and
FIG. 2. Inhibitory effects of different brands of commercially available cranberry
juices (A) and the various fractions generated from the most potent juice (from
vendor E) (B) on the 1-hydroxylation of midazolam in human intestinal micro-
somes known not to express CYP3A5. To avoid any perceived conflicts of interest,
the identities of the juices were coded as vendors A, B, C, D, and E. Hex,
hexane-soluble fraction; Chlor, chloroform-soluble fraction; BuOH, butanol-soluble
fraction; Aq, aqueous-soluble fraction; BLQ, below limit of quantification. Bars and
error bars denote mean and S.D., respectively, of triplicate incubations. Control
activity averaged 87 (A) or 65 (B) pmol/min/mg microsomal protein. , p  0.05
versus 0.05% corresponding juice (A) or 10 g/ml corresponding juice fraction (B);
#, p  0.05 versus juice A at 0.05% (A) or hexane-soluble fraction at 10 g/ml (B);
†, p  0.05 versus juice A at 0.5% (A) or hexane-soluble fraction at 50 g/ml (B);
‡, p  0.05 versus juice B at 0.5% (A) or chloroform-soluble fraction at 50 g/ml
(B) (two-way ANOVA, followed by Tukey’s test).
FIG. 3. Inhibitory effects of cranberry juice E on midazolam 1-hydroxylation
activity in rCYP3A4 and rCYP3A5 enzymes. Bars and error bars denote mean and
S.D., respectively, of triplicate incubations. BLQ, below limit of quantification.
Control activity averaged 1.3 (rCYP3A4) or 1.7 (rCYP3A5) pmol/min/pmol. , p 
0.05 versus 0.05% juice; #, p  0.05 versus rCYP3A4 at 0.05% juice (two-way
ANOVA, followed by Tukey’s test).
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cranberry juice-supplemented conditions was 19.4 
 1.8  106,
21.9 
 3.3  106, 18.9 
 2.8  106, and 12.0 
 2.4 106 cm/s,
respectively. A significant difference in Papp was detected between
control and cranberry juice treatment and between the acidic and
cranberry juice treatments. From 1 h onward, compared with control
conditions, only cranberry juice significantly altered midazolam ab-
sorption (Fig. 5). The amount of drug appearing in the basolateral
compartment was lower in the presence of cranberry juice at all the
time points, by 34 to 47%. The total amount of midazolam recovered
from the apical and basolateral chambers was 80% of the initial
amount added to the apical chamber at all the time points and under
all the conditions. The amount of midazolam recovered from cell
scrapings at the end of the 4-h experiment was similar among all four
conditions (7–9% of the initial amount added to the apical chamber).
Effects of Cranberry Juice E on Midazolam Pharmacokinetics.
The effects of double-strength cranberry juice E were compared with
water on the oral pharmacokinetics of midazolam in 16 healthy
participants. Because the causative ingredient(s) underlying a poten-
tial midazolam-cranberry juice interaction were/are not known, along
with the fact that natural products vary substantially in the composi-
tion of bioactive ingredients (Paine and Oberlies, 2007), multiple
glasses of double-strength juice were given to maximize the ability to
detect an interaction; a similar approach was taken routinely in early
drug-grapefruit juice interaction studies (Bailey et al., 1991; Kane and
Lipsky, 2000), when the causative ingredients in grapefruit juice were
not known. The sweetened double-strength cranberry juice was well
tolerated by the majority of the subjects. Most of the subjects reported
drowsiness, which is a common side effect of midazolam. Two of the
subjects experienced mild nausea, but no vomiting episodes were
reported. All of the reported side effects resolved within a few hours.
In general, midazolam was absorbed rapidly when taken with
water, with a median time to peak concentration occurring within 30
min (Fig. 6; Table 1). In each of the 16 subjects, compared with water,
cranberry juice E slowed the absorption of midazolam, as evidenced
by an increase in Tmax, coupled with a decrease in Cmax. The increase
in Tmax varied from 2- to 8-fold, and the decrease in Cmax varied from
4 to 70%. Median Tmax was increased significantly by 6-fold, and the
geometric mean Cmax was decreased significantly by 44% (Table 1).
For both phases, the percentage of the AUC0-	 extrapolated to infinite
time was less than 15% in the majority of the subjects (n  14) and
was at most 24%. Compared with water, cranberry juice E increased
the AUClast and AUC0-	 in all but four subjects; among all the
subjects, the -fold change ranged from 0.9- to 2.6-fold and from 0.9-
to 2.7-fold, respectively. The geometric mean AUClast and AUC0-	
were increased significantly, by approximately 30%, respectively
(Fig. 6; Table 1). Correspondingly, in all but four subjects, cranberry
juice E decreased midazolam Cl/F; among all the subjects, the differ-
ence ranged from 63 to 15% (Fig. 7A). The geometric mean Cl/F
was decreased significantly by 25% (Table 1). The geometric mean
terminal t1/2 was not significantly different between the two treat-
ments (Table 1).
The formation of 1-hydroxymidazolam was rapid, regardless of
treatment, as exemplified by the simultaneous appearance with mida-
zolam in the systemic circulation (Fig. 6). Accordingly, the median
Tmax of the metabolite was similar to that of the parent, regardless of
treatment (p  0.09) (Table 1). Moreover, as with midazolam, cran-
berry juice slowed the systemic appearance of 1-hydroxymidazolam
relative to water. Median Tmax was increased significantly, by 4-fold,
and the geometric mean Cmax was decreased significantly by 68%
(Table 1). For both treatments, the percentage of the AUC0-	 extrap-
olated to infinite time was less than 15% in most of the subjects (n 
12) and did not exceed 22%. Compared with water, cranberry juice E
decreased the AUClast and AUC0-	 of 1-hydroxymidazolam in all but
three subjects; among all the subjects, the difference ranged from
approximately 47 to 24%. The geometric mean AUClast and
AUC0-	 were decreased significantly by 20 and 16%, respectively
(Fig. 6; Table 1). The systemic elimination of 1-hydroxymidazolam
during the water phase showed formation rate-limited kinetics, as
exemplified by the similar geometric mean terminal t1/2 between
midazolam and 1-hydroxymidazolam (p  0.35) (Table 1). Cran-
berry juice E appeared not to alter the systemic elimination of the
metabolite (p  0.20). Consistent with the effect of juice E on
FIG. 4. Inhibitory effects of the various fractions gen-
erated from cranberry juice E on midazolam 1-hy-
droxylation activity in rCYP3A4 (A) and rCYP3A5 (B)
enzymes. Hex, hexane-soluble fraction; Chlor, chloro-
form-soluble fraction; BuOH, butanol-soluble fraction;
Aq, aqueous-soluble fraction. Bars and error bars de-
note mean and S.D., respectively, of triplicate incuba-
tions. Control activity averaged 1.0 (A) or 1.4 (B) pmol/
min/pmol recombinant enzyme. , p  0.05 versus 10
g/ml corresponding juice fraction; #, p  0.05 versus
hexane-soluble fraction at 10 g/ml; †, p  0.05 versus
hexane-soluble fraction at 50 g/ml; ‡, p  0.05 versus
chloroform-soluble fraction at 50 g/ml (two-way
ANOVA, followed by Tukey’s test).
FIG. 5. Effects of high sugar content (50 g/l, pH 7.4), low pH (5.5), and 25%
cranberry juice E (pH 7.4) on the appearance of midazolam in the basolateral
compartment of Caco-2 cell monolayers. Symbols and error bars denote mean and
S.D., respectively, of triplicate culture inserts. , p  0.05 versus all the other
conditions (two-way ANOVA with repeated measures, followed by Tukey’s test).
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midazolam Cl/F (Fig. 7A), relative to water, both the partial and total
metabolite/parent AUC ratios were decreased in all but three subjects
(Fig. 7B); among all the subjects, the difference ranged from 63 to
1% and from 66 to 1%, respectively. The geometric means of the
partial and total metabolite/parent AUC ratios were decreased signif-
icantly by 40% (Table 1).
Discussion
Based on the inconsistencies in the literature regarding whether
cranberry juice can elicit clinically relevant interactions with certain
medications, coupled with the inherent difficulties that can arise when
evaluating the drug interaction liability of a natural product, the
current work was undertaken to address three objectives. The first was
to determine whether cranberry juice has any interaction liability with
drugs that undergo extensive first-pass metabolism by enteric CYP3A.
As aforementioned, it remains unclear whether the in vivo inconsis-
tencies reflect species differences, study design/sample size, and/or
variability of the natural product study materials. The second objec-
tive was to show that natural product study materials, all seemingly of
the same content, can act distinctly from each other, both chemically
and biologically. A drug-natural product interaction study in the
universal sense is impossible because natural products vary consider-
ably based on a host of factors, including climate, growing season, and
processing procedures (Paine and Oberlies, 2007). Accordingly, it
seems premature to draw broad conclusions from an investigation of
one brand of the natural product. The third objective was to develop
a more rigorous in vitro-in vivo approach that can be used prospec-
tively to evaluate the drug interaction liability of a dietary substance.
That is, if current models are inappropriate, how can we better
investigate the drug interaction potential of a dietary component? Do
we wait for a serendipitous observation, as with grapefruit juice
(Bailey et al., 1991), or do we examine one brand chosen randomly,
as apparently occurred in recent studies? To address this issue, well
established techniques used to characterize drug disposition were
combined with those used to characterize natural products (Paine and
Oberlies, 2007).
The inhibitory effects of different brands of cranberry juice were
evaluated first on enteric CYP3A-mediated metabolism using a rele-
vant human-derived in vitro system and an established probe substrate
that can be given to humans. Consistent with the general interbrand
variation in natural products regarding the composition of bioactive
components, the extent of inhibition varied considerably among just
five brands tested, ranging from 34% to abolishment. Such interbrand
variability is undoubtedly much greater in the broader marketplace. If
such a scenario were to occur with five different lots of a drug, a
single lot would not be considered representative of all the others.
Likewise, a single brand/lot of cranberry juice would not be repre-
sentative of the entire marketplace.
The most potent of the tested juices (E) was selected for further
characterization, which was to fractionate the juice to produce a
hexane-, chloroform-, butanol-, and aqueous-soluble fraction and to
evaluate the effects of each on enteric CYP3A activity. The hexane-
and chloroform-soluble fractions showed the greatest extent of inhi-
bition in both HIMs and rCYP3A4 and were concentration-dependent,
indicating that the CYP3A inhibitors in juice E resided largely in these
two more lipophilic fractions. As has been reported for several ther-
apeutic agents, including ketoconazole, fluconazole, diltiazem, and
mifepristone (Isoherranen et al., 2008), the whole juice (at the lower
concentration), as well as the chloroform-soluble fraction (at the
higher concentration), showed greater inhibition toward rCYP3A4
than rCYP3A5. Further purification of the hexane- and chloroform-
soluble fractions is ongoing to identify the inhibitory compound(s),
which will enable the determination of whether juice E, and cranberry
juice in general, contains a selective CYP3A4 inhibitor.
Potential physicochemical effects of cranberry juice E were eval-
uated next on the absorptive permeability of midazolam in Caco-2
cells, a human intestinal cell line used routinely as a model of the
small intestinal epithelium (Press and Di Grandi, 2008). Compared
with control conditions, only juice E altered midazolam absorption
significantly. As reflected in the Papp values, juice E (pH adjusted to
7.4), but not high sugar content or low pH conditions, slowed mida-
zolam appearance in the basolateral compartment. From 1 h onward,
midazolam concentration in the basolateral compartment was always
lower than that under all the other conditions by at least 34%. The
similar total recoveries of midazolam from the apical and basolateral
compartments at all the time points (80%), as well as from the cell
scrapings at the end of the 4-h experiment (8%), under all the
conditions indicated that these observations were not artifacts of the
HPLC/MS/MS method.
As proof of concept, the effects of cranberry juice E were compared
with water on the oral pharmacokinetics of midazolam in healthy
volunteers. Unlike the two clinical studies that showed no interaction
between a different cranberry juice product and cyclosporine (Grenier
et al., 2006) or midazolam (Lilja et al., 2007), but consistent with
current observations from Caco-2 cells, juice E decreased the rate of
midazolam absorption, as evidenced by a 6-fold increase in Tmax and
40% decrease in Cmax. The prolonged Tmax suggested a decreased
gastric emptying rate, which may have been associated with the high
sugar content of the juice. The effects of the acidic pH of the juice
and/or stomach on the physicochemical properties of midazolam (i.e.,
ring-opening of the diazepam ring) could also have contributed to the
prolonged Tmax and decreased Cmax. However, if such an event
occurred, it seemed to be transient, as ultimately, an increase, rather
than decrease, in midazolam systemic exposure (AUC) resulted. The
lack of an effect of high sugar content and low pH conditions on
midazolam absorptive permeability in Caco-2 cells further suggested
that components inherent to cranberry juice were responsible for the
slowed absorption.
Although cranberry juice E decreased the rate of midazolam ab-
sorption, systemic exposure was enhanced significantly, as exempli-
fied by an 30% increase in AUC. The lack of effect on terminal
half-life suggested that the juice altered primarily intestinal, but not
hepatic, processes. An increase in the fraction of the midazolam dose
FIG. 6. Geometric mean concentration-time profile of midazolam (MDZ) and 1-
hydroxymidazolam (1-OH MDZ) for 16 healthy volunteers given 3  240-ml
glasses of water or sweetened double-strength cranberry juice E (CBJ) and a single
oral dose of midazolam (5 mg). Symbols and error bars denote geometric means and
upper limits of the 90% confidence interval, respectively. The 12-h time point for
midazolam during the water phase represents the geometric mean of 12 subjects.
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absorbed into the intestinal wall by juice E was unlikely because when
midazolam is given orally alone, the urinary recovery of midazolam
and metabolites is similar to that after an intravenous dose, indicating
that midazolam is absorbed completely into the intestinal wall (Heiz-
mann et al., 1983; Thummel et al., 1996; Gorski et al., 1998).
Moreover, because midazolam was given as a syrup under fasted
conditions and exhibited a Papp (10  10
6 cm/s) characteristic of
a highly permeable drug (Press and Di Grandi, 2008), regardless of
the presence of juice E, it seems unlikely that the juice shifted the
absorption of midazolam to more distal regions of the small intestine,
where CYP3A activity is lower than in more proximal regions (Paine
et al., 1997). Collectively, the enhanced AUC by juice E was probably
the result of inhibition of intestinal first-pass metabolism. The de-
crease in the 1-hydroxymidazolam/midazolam AUC ratio, resulting
from both an increase in midazolam AUC and decrease in metabolite
AUC, coupled with the observation that 1-hydroxymidazolam
tracked closely with midazolam (i.e., displayed formation rate-limited
kinetics) further support this contention. Inhibition of CYP3A-medi-
ated metabolism in the intestine rather than the liver concurs with the
in vivo study in rats (Uesawa and Mohri, 2006), arguing against
species differences as an explanation for the inconsistencies observed
in the literature.
The midazolam-cranberry juice interaction shown in the current
work may have a 2-fold clinical impact. First, the slowed absorption
may occur with other benzodiazepine receptor agonists. Short- and
intermediate-acting agents indicated for insomnia (e.g., triazolam,
zolpidem, zaleplon, eszopiclone) achieve Cmax and onset of action
within 0.5 to 2 h (Morin et al., 2007). Thus, a slowed absorption may
in turn slow the onset of sedation of drugs with effects dependent on
Cmax. Furthermore, if the mechanism is nonspecific, the scope of the
interaction may encompass other oral agents whose effects depend on
a timely onset, such as those indicated for pain and migraine. A
second clinical implication is that inhibition of intestinal first-pass
midazolam metabolism by cranberry juice may extend to other oral
CYP3A substrates. Although the average increase in midazolam AUC
was relatively modest, interindividual variability was evident among
just 16 subjects, ranging from negligible to 2.7-fold. These outcomes
are comparable with the effects of grapefruit juice on midazolam AUC
(Kupferschmidt et al., 1995; Farkas et al., 2007). Taken together, an
enhanced drug systemic exposure elicited by certain brands of cranberry
juice may increase the risk for side effects of more sensitive CYP3A
TABLE 1
Pharmacokinetics of midazolam and 1-hydroxymidazolam in 16 healthy volunteers given 3  240-ml glasses of water or sweetened double-strength cranberry juice
from vendor E (CBJ) and a single oral dose of midazolam (5 mg)
Measurea
Geometric Mean
CBJ/Water Ratio p Valueb
Water CBJ
CV % CV % 90% CI
Midazolam
Tmax (h) median (range) 0.5 (0.25–1.5) 3.0 (1.0–4.0) 0.001
Cmax (nM) 88 (44) 50 (35) 0.56 0.49–0.64 0.001
AUClast (nM  h) 197 (30) 259 (31) 1.31 1.18–1.46 0.001
AUC0-	 (nM  h) 215 (33) 286 (30) 1.33 1.17–1.50 0.001
Cl/F (l/h) 71 (33) 54 (30) 0.75 0.67–0.85 0.001
t1/2 (h) 2.9 (41) 2.9 (25) 1.01 0.86–1.19 0.93
1-Hydroxymidazolam
Tmax (h) median (range) 0.5 (0.25–1.5) 2.0 (1.0–6.0) 0.001
Cmax (nM) 33 (54) 10 (29) 0.32 0.27–0.38 0.001
AUClast (nM  h) 69 (35) 55 (23) 0.80 0.73–0.88 0.002
AUC0-	 (nM  h) 74 (37) 62 (25) 0.84 0.77–0.92 0.005
t1/2 (h) 3.2 (35) 3.3 (19) 1.04 0.89–1.20 0.68
Metabolite/parent AUC ratios
(AUCm/AUCp)last 0.34 (49) 0.21 (37) 0.001
(AUCm/AUCp)0-	 0.35 (50) 0.22 (39) 0.001
a Tmax, time to reach maximum concentration (Cmax); AUClast, area under the curve from time 0 to the last measurable concentration; AUC0-	, area under the curve from 0 to infinite h; Cl/F,
apparent oral clearance; t1/2, terminal half-life.
b Comparisons between water and CBJ for Tmax were made using the Wilcoxon signed-rank test; comparisons between water and CBJ for all the other measures were made using the paired
Student’s t-test.
FIG. 7. Effects of 3  240-ml glasses of water and sweetened double-strength
cranberry juice E (CBJ) on the oral clearance (Cl/F) (A) of midazolam and the
1-hydroxymidazolam/midazolam AUC ratio [(AUCm/AUCp)0-	] (B) in each of 16
healthy volunteers given a single oral dose of midazolam (5 mg). Open symbols and
solid lines denote individual values. Filled symbols and dashed lines denote geo-
metric mean values.
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substrates, including some HMG CoA reductase inhibitors (e.g., lova-
statin, simvastatin) and cardiovascular agents (e.g., felodipine, amioda-
rone), as well as substrates with a narrow therapeutic window (e.g.,
cyclosporine, tacrolimus) (Farkas and Greenblatt, 2008). Moreover, be-
cause of the extensive substrate overlap between CYP3A and P-gp, the
magnitude of the effect may also depend on the interplay between
CYP3A and P-gp, and/or some other transporter, in a given individual
(Paine and Oberlies, 2007). Furthermore, cranberry juice is consumed
widely by women and elderly persons (Jepson and Craig, 2008). Because
these populations also have a high rate of drug and natural product
supplement usage (Leibovitch et al., 2004; Schwartz, 2007), a large
segment of the overall population could be at risk for certain drug-
cranberry juice interactions. Finally, cranberry juice is often taken chron-
ically, sometimes at the earliest onset of UTI symptoms. Whether the
effects of long-term cranberry juice exposure on drug disposition are
more pronounced than acute exposure merits further investigation.
In summary, a systematic approach, which began with in vitro
testing and culminated with a proof-of-concept clinical study, enabled
the identification of a cranberry juice product that elicited a pharma-
cokinetic interaction with an established CYP3A probe substrate. This
approach limited the need for conducting more time-consuming and
costly clinical studies to compare the effects of different brands of
juice. Moreover, unlike the production of drug products, the profile of
secondary metabolites in natural products varies substantially. That is,
whereas a pharmaceutical agent has a defined molecular formula and
chemical structure, regardless of the manufacturer, there are hundreds
of constituents in “cranberry juice,” and the profile of such constitu-
ents can vary considerably between growing conditions, formulations,
brands, and even lots within the same brand. The scientific literature
is replete with claims, both positive and negative, about herbal prod-
ucts and other dietary substances, typically referring to such products
in a general sense (e.g., cranberry, St. John’s wort). The current work
substantiates that rigorous in vitro characterization of dietary sub-
stances should be undertaken before initiation of clinical drug-diet
interaction studies.
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